12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vyndaqel tafamidis meglumine regulatory update

The German Institute for Quality and Efficiency in Healthcare (IQWiG) said Vyndaqel tafamidis from Pfizer plus best supportive care provides a "small degree" of additional benefit compared with best supportive care alone in the treatment of transthyretin (TTR) familial amyloid polyneuropathy (FAP). Best supportive care is...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >